


January 22, 2024

J-Pharma Co., Ltd.

**J-Pharma Presented the latest findings on LAT1 inhibitor *NANVURANLAT* (development code: JPH203) at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI2024)**

J-Pharma Co. Ltd. (Headquarters: Yokohama, Kanagawa Prefecture, President & CEO Masuhiro Yoshitake) announces the latest findings on its LAT1 inhibitor *Nanvuranlat* were presented in a poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2024) held in San Francisco, California, USA.



1. Poster Session:

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

2. Date and Time: January 19, 2024, 12:30 - 14:00 (local time)

3. Abstract Number: 483

4. Abstract Title

Treatment outcomes by stratifying the N-acetyl transferase 2 phenotype in pre-treated patients with advanced refractory biliary tract cancer treated with nanvuranlat: An ad-hoc analysis of a randomized, double-blind, placebo-controlled phase 2 study.

5. First Presenter

Dr. Naohiro Okano, M.D., Ph.D  
Assistant Professor, Department of Medical Oncology,  
School of Medicine, Kyorin University Faculty of Medicine

**[For further information, please contact.]**

J-Pharma Co., Ltd.,  
Administration Department, Public Relations

TEL: 045-506-1155

FAX: 045-506-1156

Mail: [info@j-pharma.com](mailto:info@j-pharma.com)